Rick,
Don't think anyone else has taken you up on your challenge, but here's my two cents:
I spotted this, which sounded interesting:
<< Obesity Lead Optimization: Discovered a series of
compounds that increase the circulating level of a protein that causes weight loss in animals.>>
Sure sounds like leptin. So I dug further down and found:
<< We have identified a series of compounds in this assay
that increase leptin in the blood of laboratory animals. We have commenced additional studies of the mechanism by which these compounds regulate the Ob gene.>>
This is way cool. They're probably pretty far from a drug, but intellectually it's very interesting. I would love to know what these compounds look like.
Also potentially very interesting:
<< {TLRK scientists have discovered} a drug candidate that completely inhibits STAT6 function in cells,
validating the underlying basis of this approach. The structures of several
proprietary STAT6 inhibitors bound to specific sites on the target protein have
been determined by X-ray crystallography and are being utilized to guide our
chemistry effort.>>
With a co-crystal structure in hand, they should be able to do some serious damage in this area. Note, however, that the statement refers to more than one binding site. Sounds like there is still a long way to go before they identify the key binding site(s) and hence which series to optimize.
Scientifically, there is a lot to be interested in. Financially, with only about 6 million shares potentially trade-able today, I'll wait for the 180 day lockout period to end when another 33 million shares are freed up.
There is some interesting info in the financials, as well, but this post is long enough, and I hear someone crying.
TD |
